CLEVELAND--(BUSINESS WIRE)--ClinicalRM, Inc. and the Ohio Clinical Trials Collaborative (OCTC) announce a co-marketing partnership offering joint services for clinical trials of new biologics, drugs and medical devices. The relationship will serve the organizations’ mutual customers with a full spectrum of development services, including access to a network of veteran investigators, patient population identification, clinical operations, and guidance on medical/regulatory affairs.
“ClinicalRM is pleased to align forces with the OCTC. Expedited access to Ohio’s premier medical institutions will shorten the time to start a new multisite clinical trial as well as assure timely patient enrollment for our clients,” said Alan Braverman, PharmD, Vice President of Clinical Operations of ClinicalRM, a 20-year-old full-service contract research organization headquartered in NE Ohio. The firm has over 350 scientific, clinical, and other personnel dedicated to providing strong clinical trial services and support.
The pharmaceutical industry faces a challenging and expensive process for the conduct of clinical trials. The OCTC offers centralized access to Ohio’s premier medical centers for clinical trial development. It is a statewide initiative that streamlines contracting, budgeting, approval of human subject use and patient recruitment/enrollment processes to move medical discoveries to market faster. ClinicalRM, a full-service contract research organization (CRO), supports these clinical trials with an array of clinical operations, quality management, and regulatory affairs services, along with a regional and globally experienced scientific advisory board.
“Integrating ClinicalRM’s services into the OCTC’s clinical trials network will provide a powerful engine for new pharmaceutical, biologic and medical device development in Ohio,” said John Peterson, PhD, Global Business Development Director of the OCTC.
Founded in 1994, ClinicalRM is a full service CRO specializing in preclinical through Phase IV support of clinical trial services for biologics, drugs, and devices. Through international partnerships and a global selection of sites, they support their customers with a wide array of research, regulatory, and sponsor services that are tailored to accommodate clinical trials globally. Spanning the government, academic, and commercial marketplaces, ClinicalRM’s multi-therapeutic team consists of leading experts in the fields of Infectious Disease, Oncology/Hematology, Vaccine Development and Neurotherapeutics. ClinicalRM’s goal is simple—to assist in improving the quality of life in communities throughout the world by advancing the goals of their customers. For more information, please go to www.clinicalrm.com.
About the Ohio Clinical Trials Collaborative
The OCTC is an initiative under Governor John Kasich’s vision of a premier research medical corridor in Ohio that is co-founded by the Clinical and Translational Science Collaborative at Case Western Reserve University, the Center for Clinical and Translational Science at The Ohio State University and the Center for Clinical and Translational Science and Training at the University of Cincinnati. With offices at Case Western Reserve University’s School of Medicine, the OCTC seeks to establish Ohio as one of the most efficient and effective states in which to test new medications and treatment strategies. The OCTC offers economies of scale and unique capacity, leveraging expertise from across the state of Ohio to conduct clinical trials on behalf of industry sponsors. For more information, please go to www.ohioclintrials.org.